Alita Hassan, MPH
Senior Advisor, Early Access ProgramsAlita is an epidemiologist with over 25 years of clinical research experience in pharmaceutical R&D, working for pharmaceutical companies and Contract Research Organizations (CROs). She has served as the program lead for several expanded access programs for cardiovascular and metabolic diseases, oncology, rare disease indications, and neurologic disorders. Her previous experience includes leading a Global Compassionate Use program for HoFH patients for Lipitor, while at Pfizer Inc. Alita has experience as an Early Clinical Development Lead and has authored strategic clinical development plans, inclusive of Expanded Access / Compassionate use, while at Pfizer Inc. She subsequently became Executive Director of Global Feasibility and Strategic Project Development for a global CRO, and in that role chaired the Rare Disease and Orphan Indication Work Group. She has led strategic cross-functional discussions with global teams, including KOLs, advocacy groups, patients, and regulatory affairs and submissions teams. Alita has deep expertise in post-trial access strategy and leadership and the execution of global programs. Alita is a graduate of the University of Michigan, for both Bachelor of Science and Master in Public Health. Alita is actively involved and holds Board positions for non-profit organizations supporting communities in Michigan.